Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardiff Oncology (CRDF) FCF Margin (2016 - 2025)

Historic FCF Margin for Cardiff Oncology (CRDF) over the last 15 years, with Q3 2025 value amounting to 9043.33%.

  • Cardiff Oncology's FCF Margin fell 27063600.0% to 9043.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 8436.53%, marking a year-over-year decrease of 34070600.0%. This contributed to the annual value of 5530.45% for FY2024, which is 9181100.0% up from last year.
  • Per Cardiff Oncology's latest filing, its FCF Margin stood at 9043.33% for Q3 2025, which was down 27063600.0% from 6158.68% recorded in Q2 2025.
  • Cardiff Oncology's 5-year FCF Margin high stood at 3814.63% for Q1 2024, and its period low was 14081.08% during Q1 2022.
  • Over the past 5 years, Cardiff Oncology's median FCF Margin value was 6720.37% (recorded in 2023), while the average stood at 7497.88%.
  • Its FCF Margin has fluctuated over the past 5 years, first surged by 67781400bps in 2024, then crashed by -87505000bps in 2025.
  • Over the past 5 years, Cardiff Oncology's FCF Margin (Quarter) stood at 5636.84% in 2021, then tumbled by -31bps to 7394.53% in 2022, then surged by 38bps to 4581.41% in 2023, then plummeted by -48bps to 6799.34% in 2024, then crashed by -33bps to 9043.33% in 2025.
  • Its last three reported values are 9043.33% in Q3 2025, 6158.68% for Q2 2025, and 12565.14% during Q1 2025.